Skip to NavigationSkip to content

Business Services

Top Ten most popular articles on this week!

This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK announced redundancies as Janssen scored twice in Phase 3 trials in chronic kidney disease and HIV.

Insys Therapeutics names current CFO Andrew Long as company's new CEO

Published on: 17/04/19

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s new CEO.

The opioid drugmaker said the decision had come after Motahari agreed to step down from the position of President and CEO.

The firm, who have faced legal issues over the marketing of their fentanyl based spray Subsys, have seen a series of successions in recent years after CEO Michael Babich was arrested in 2016.

The company were thus keen to emphasise their leadership in the “development, manufacture and commercialization of pharmaceutical cannabinoids.”

Medical cannabis: A green light for patients in need?

Published on 15/04/19 at 10:00am

Spinnaker Opportunities announced in February it had reached a preliminary agreement to acquire cannabis oil-focused research firm Kanabo Research and its growing portfolio of activities. Spinnaker Chairman Andy Morrison explains the move towards medical cannabis, and the opportunities and challenges ahead for healthcare as attitudes towards the drug slowly shift.

Can you provide a bit of background on Spinnaker?

Bayer VP elected to two of the firm’s executive committees

Published on: 12/04/19

Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management to lead both the Bayer Science Foundation and the Bayer Cares Foundation.

Her new leadership roles will be merged with her current responsibilities as Vice President, Head of Corporate Innovation and R&D at the firm.

Daiichi Sankyo name current COO Sunao Manabe as firm's new CEO

Published on: 12/04/19

Daiichi Sankyo have said Sunao Manabe, the company’s current COO will take over from George Nakayama as the firm’s new Chief Executive Officer (CEO).

Manabe, who joined Sankyo Co in 1978, has, since joining the firm, taken on roles of increasing seniority. The company veteran took on the position of President and COO in 2017.

The move from COO to CEO is a familiar pattern in Japanese firms mirrored in Takeda’s appointment of Frenchman Christophe Weber in 2014.

GW Pharma announce Darren Cline as company's new Chief Commercial Officer

Published on: 12/04/19

GW Pharmaceuticals have announced the appointment of Darren Cline as the company’s new US Chief Commercial Officer. Cline will lead the commercialisation of cannabidiol (CBD) based epilepsy medication Epidiolex in the United States.

Cline will succeed Julian Gangolli who announced he would be stepping down from his current role as President of GW Pharma’s US subsidiary, Greenwich Biosciences, in November 2018.

Cline is expected to start in his new role on 22 April 2019. Cline will however work with Gangolli for several weeks as he transitions into the organisation.

Top Ten most popular articles on this week!

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile Britain’s cost effectiveness body NICE turned down Astellas’ Xtandi in prostate cancer.

Nevertheless our top story looked at Gilead’s announcement they would be laying off one fifth of their workforce. The news came as shares in Indivior plummeted by as much as 70% amid fraud allegations.

Living with a rare chromosome disorder

Published on 11/04/19 at 12:28pm

Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 people worldwide. She recounts the struggle to secure a diagnosis, and how the experience shaped her attitude on how we confront rare disease.

Can you shed some light on the nature of Inv Dup Del 8p?

Kymab announces Merck exec Simon Sturge as new CEO

Published on: 08/04/19

UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins from current CEO and Cambridge Antibody Technology co-founder David Chiswell effective 1 May.

The decision marks a next chapter in an international career spanning more than three decades in pharma and biotechnology; Sturge most recently served at Merck as its Executive Vice President Global Strategy, Business Development & Global Operations.

Protecting public health: Is real-world evidence the key?

Published on 08/04/19 at 01:49pm

In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need to deliver treatments and preventative therapies is a key concern for industry and national healthcare bodies. Matt Fellows explores how incorporating wider use of real-world evidence into these systems could be the solution we need.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches